Health care startups in Massachusetts, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
| TraceLink | North Reading | Series D | $93.0M | 2018-08-21 |
| WHOOP | Boston | Series G | $575.0M | 2026-03-31 |
| Iterative Health | Cambridge | Series C | $77.0M | 2026-04-30 |
| PhaseV | Boston | Series A | $50.0M | 2025-05-13 |
| Origin | Boston | Series B | $56.0M | 2021-08-30 |
| VideaHealth | Boston | Series B | $40.0M | 2025-01-28 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,220 health care startups in Massachusetts, United States have raised $54.7B in total.
- 155 of them closed their most recent round in the last 12 months, $5.1B combined.
- The largest of those rounds is WHOOP's $575.0M Series G, dated March 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- MassChallenge is an investor in 28 of them, more than any other fund.
- Biotech is the most common other sector, with 652 companies (53%).
- 34% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (43% of companies with a recorded size).
- 6 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,220| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| UltraSight | UltraSight applies machine learning to ultrasound to support more accurate and timely clinical decisions. | Health care | Cambridge | Series B | $24.0M | 2026-09-23 | $39.0M | Yozma Group | 11 to 50 | 2018 |
| Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| INIA Biosciences | INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. | Biotech | Boston | Seed | $1.5M | 2026-09-08 | $1.5M | MassChallenge, MedTech Innovator | 1 to 10 | 2020 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| Remedium Bio | Remedium Bio develops gene therapy treatments for various diseases. | Biotech | Needham | Series A | $10.0M | 2026-08-10 | $13.8M | National Science Foundation, MicroVentures, Longevitytech.fund +1 | 11 to 50 | 2020 |
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Boston | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| InStockRx | InStockRx connects licensed pharmacies to buy and sell inventory with each other. | Commerce | Boston | Series A | $5.0M | 2026-07-01 | $5.1M | Techstars | 1 to 10 | 2020 |
| Xellar Biosystems | Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. | Artificial intelligence | Newton | Series A | $29.5M | 2026-06-30 | $93.2M | Legend Capital, Tiantu Capital, Zhengxuan Investment +1 | 11 to 50 | 2022 |
| Cartwheel | Cartwheel makes first aid products for families, starting with head lice treatments. | Health care | Boston | Seed | $557K | 2026-06-25 | $557K | Health Wildcatters | 1 to 10 | 2023 |
| Portal | Portal engineers cells to develop new treatments and therapies. | Biotech | Watertown | Seed | $9.0M | 2026-06-18 | $25.7M | Pear VC, Page One Ventures, IA Ventures +2 | 11 to 50 | 2023 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| InStride Health | InStride Health provides evidence-based OCD and anxiety treatment to children and teenagers. | Health care | Boston | Series C | $30.0M | 2026-06-15 | $86.0M | General Catalyst, .406 Ventures, Mass General Brigham Ventures +2 | 251 to 500 | 2021 |
| CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Boston | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Iterative Health | Iterative Health develops technology to improve patient access to healthcare across different socioeconomic and geographic areas. | Artificial intelligence | Cambridge | Series C | $77.0M | 2026-04-30 | $268.6M | Plug and Play, Alumni Ventures, Insight Partners +1 | 251 to 500 | 2017 |
| AcuityMD | AcuityMD provides AI-powered data analysis to help companies make informed commercial decisions in healthcare. | Artificial intelligence | Boston | Series C | $80.0M | 2026-04-21 | $163.0M | Redpoint, Benchmark, ICONIQ Growth +2 | 251 to 500 | 2019 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Beacon Biosignals | Beacon Biosignals uses neurotechnology to measure brain activity for clinical trials and patient treatment. | Artificial intelligence | Boston | Series B | $11.0M | 2026-04-06 | $127.0M | General Catalyst, Half Court Ventures, Indicator Ventures +1 | 101 to 250 | 2019 |
| WHOOP Unicorn | WHOOP sells wearable fitness devices and a subscription service that tracks physiological data for performance insights. | Hardware | Boston | Series G | $575.0M | 2026-03-31 | $979.8M | Founder Collective, SoftBank Vision Fund, Foundry Group +2 | 501 to 1,000 | 2012 |
| EnVision Endoscopy | EnVision Endoscopy supplies medical devices and solutions used in endoscopic surgeries. | Health care | Lowell | Series A | $500K | 2026-03-30 | $3.9M | MassChallenge, National Science Foundation, MassVentures +1 | 1 to 10 | 2018 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Flourish Care | Flourish Care provides childbirth education, birth planning, and newborn care services. | Commerce | Boston | Seed | $5.7M | 2026-03-18 | $5.7M | MassChallenge, Texas HALO Fund | 11 to 50 | 2020 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| Coral Care | Coral Care connects families with licensed speech, occupational, and physical therapists through a pediatric therapy platform. | Health care | Boston | Series A | $13.0M | 2026-02-23 | $19.5M | Hustle Fund, Reach Capital, AlleyCorp +2 | 11 to 50 | 2023 |
| Gelmedix | Gelmedix develops a biomaterial platform that improves drug delivery for complex eye treatments. | Biotech | Newton | Seed | $13.0M | 2026-02-17 | $15.4M | Safar Partners, EQx Fund, HTL Innovations | 1 to 10 | 2020 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
Table 1. Health care startups in Massachusetts, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,220.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | WHOOP Unicorn | WHOOP sells wearable fitness devices and a subscription service that tracks physiological data for performance insights. | Hardware | Boston | Series G | $575.0M | 2026-03-31 | $979.8M | Founder Collective, SoftBank Vision Fund, Foundry Group +2 | 501 to 1,000 | 2012 |
| 2 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 3 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 4 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 5 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 6 | CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| 7 | AcuityMD | AcuityMD provides AI-powered data analysis to help companies make informed commercial decisions in healthcare. | Artificial intelligence | Boston | Series C | $80.0M | 2026-04-21 | $163.0M | Redpoint, Benchmark, ICONIQ Growth +2 | 251 to 500 | 2019 |
| 8 | Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| 9 | Iterative Health | Iterative Health develops technology to improve patient access to healthcare across different socioeconomic and geographic areas. | Artificial intelligence | Cambridge | Series C | $77.0M | 2026-04-30 | $268.6M | Plug and Play, Alumni Ventures, Insight Partners +1 | 251 to 500 | 2017 |
| 10 | Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
Table 2. Health care startups in Massachusetts, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | MassChallenge | Startup accelerator | Boston, United States | 28 | 2% | 4 | INIA Biosciences, EnVision Endoscopy, Flourish Care |
| 2 | Techstars | Startup accelerator | New York, United States | 17 | 1% | 1 | InStockRx |
| 3 | RA Capital Management | Startup incubator | Boston, United States | 14 | 1% | 4 | Delix Therapeutics, Superluminal Medicines, Terrestrial Bio |
| 4 | Alumni Ventures | Angel group | Manchester, United States | 13 | 1% | 1 | Iterative Health |
| 5 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 13 | 1% | 4 | Remedium Bio, Kytopen, EnVision Endoscopy |
| 6 | Y Combinator | Startup accelerator | Mountain View, United States | 12 | 1% | 1 | Benchify |
| 7 | F-Prime | Venture capital firm | Cambridge, United States | 11 | 1% | 1 | Nocion Therapeutics |
| 8 | Google Ventures | Corporate venture arm | San Francisco, United States | 11 | 1% | 1 | Cerevance |
| 9 | Polaris Partners | Private equity firm | Boston, United States | 10 | 1% | 1 | Triveni Bio |
| 10 | MassVentures | Venture capital firm | Boston, United States | 10 | 1% | 2 | Kytopen, EnVision Endoscopy |
| 11 | .406 Ventures | Venture capital firm | Boston, United States | 8 | 1% | 2 | InStride Health, FamilyWell Health |
| 12 | Invus | Private equity firm | New York, United States | 8 | 1% | 1 | Triveni Bio |
| 13 | General Catalyst | Venture capital firm | San Francisco, United States | 7 | 1% | 2 | InStride Health, Beacon Biosignals |
| 14 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 7 | 1% | ||
| 15 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 7 | 1% | 2 | Triveni Bio, Kytopen |
Table 3. Health care startups in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 652 | 53% | $43.6B |
| Software | 290 | 24% | $9.0B |
| Artificial intelligence | 143 | 12% | $5.8B |
| Hardware | 62 | 5% | $2.2B |
| Commerce | 32 | 3% | $187.8M |
| Fintech | 20 | 2% | $265.3M |
| Education | 19 | 2% | $112.5M |
| Energy | 4 | 0% | $4.5M |
| Cybersecurity | 4 | 0% | $9.8M |
Table 4. Health care startups in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Health care startups in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Health care startups in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 7 | 5% | $177.3M |
| October 2026 | 7 | 5% | $342.3M |
| September 2026 | 15 | 10% | $503.1M |
| August 2026 | 16 | 10% | $478.7M |
| July 2026 | 8 | 5% | $151.2M |
| June 2026 | 18 | 12% | $578.3M |
| May 2026 | 4 | 3% | $146.8M |
| April 2026 | 14 | 9% | $440.2M |
| March 2026 | 14 | 9% | $917.5M |
| February 2026 | 11 | 7% | $86.2M |
| January 2026 | 22 | 14% | $707.0M |
| December 2025 | 13 | 8% | $348.5M |
| November 2025 | 6 | 4% | $210.2M |
Table 7. Health care startups in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 136 | 11% | $4.5B |
| 2025 | 152 | 12% | $4.6B |
| 2024 | 107 | 9% | $3.5B |
| 2023 | 107 | 9% | $4.4B |
| 2022 | 128 | 10% | $3.5B |
| 2021 | 117 | 10% | $3.4B |
Table 8. Health care startups in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 150 | 12% |
| 2020 to 2022 | 262 | 22% |
| 2015 to 2019 | 402 | 33% |
| 2010 to 2014 | 209 | 17% |
| Before 2010 | 179 | 15% |
Table 9. Health care startups in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 452 | 38% |
| 11 to 50 | 517 | 43% |
| 51 to 100 | 110 | 9% |
| 101 to 250 | 72 | 6% |
| 251 to 500 | 22 | 2% |
| 501 to 1,000 | 12 | 1% |
| 1,001 to 5,000 | 3 | 0% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 2 | 0% |
Table 10. Health care startups in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 1,220 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,220 rows: 223 have no round amount, 0 no city and 165 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Massachusetts, United States are on the list?
- 1,220, in the file dated 16 November 2026. 155 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,220 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.